BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 18630122)

  • 21. Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers.
    Toyama T; Yamashita H; Kondo N; Okuda K; Takahashi S; Sasaki H; Sugiura H; Iwase H; Fujii Y
    BMC Cancer; 2008 Oct; 8():309. PubMed ID: 18950515
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Flow cytometric analysis of estrogen, progesterone receptor expression and DNA content in formalin-fixed, paraffin-embedded human breast tumors.
    Redkar AA; Krishan A
    Cytometry; 1999 Apr; 38(2):61-9. PubMed ID: 10323218
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A region close to Tp53 shows LOH in familial breast cancer.
    Luo L; Chen J; Du Q; Dumanski J; Blennow E; Kockum I; Luthman H; Lindblom A
    Int J Mol Med; 2002 Apr; 9(4):405-9. PubMed ID: 11891537
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-throughput amplicon scanning of the TP53 gene in breast cancer using high-resolution fluorescent melting curve analyses and automatic mutation calling.
    Bastien R; Lewis TB; Hawkes JE; Quackenbush JF; Robbins TC; Palazzo J; Perou CM; Bernard PS
    Hum Mutat; 2008 May; 29(5):757-64. PubMed ID: 18348286
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Estimation of hormone receptor status in fine-needle aspirates and paraffin-embedded sections from breast cancer using the novel rabbit monoclonal antibodies SP1 and SP2.
    Cano G; Milanezi F; Leitão D; Ricardo S; Brito MJ; Schmitt FC
    Diagn Cytopathol; 2003 Oct; 29(4):207-11. PubMed ID: 14506673
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BRCA1/BRCA2 mutation status and analysis of cancer family history in participants of the Royal Marsden Hospital tamoxifen chemoprevention trial.
    Kote-Jarai Z; Powles TJ; Mitchell G; Tidy A; Ashley S; Easton D; Assersohn L; Sodha N; Salter J; Gusterson B; Dowsett M; Eeles R
    Cancer Lett; 2007 Mar; 247(2):259-65. PubMed ID: 16777318
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic role of HuR in hereditary breast cancer.
    Heinonen M; Fagerholm R; Aaltonen K; Kilpivaara O; Aittomäki K; Blomqvist C; Heikkilä P; Haglund C; Nevanlinna H; Ristimäki A
    Clin Cancer Res; 2007 Dec; 13(23):6959-63. PubMed ID: 18056170
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The estrogen receptor alpha C975G variant in familial and sporadic breast cancer: a case-control study.
    Skoglund J; Margolin S; Zhou XL; Maguire P; Werelius B; Lindblom A
    Anticancer Res; 2006; 26(4B):3077-81. PubMed ID: 16886637
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ethnicity delineates different genetic pathways in malignant glioma.
    Chen P; Aldape K; Wiencke JK; Kelsey KT; Miike R; Davis RL; Liu J; Kesler-Diaz A; Takahashi M; Wrensch M
    Cancer Res; 2001 May; 61(10):3949-54. PubMed ID: 11358811
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of estrogen and progesterone receptors in cytologic specimens using various fixatives.
    Hudock JA; Hanau CA; Christen R; Bibbo M
    Diagn Cytopathol; 1996 Jul; 15(1):78-83. PubMed ID: 8807259
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Polymorphism of TP53 codon 72 showed no association with breast cancer in Iranian women.
    Khadang B; Fattahi MJ; Talei A; Dehaghani AS; Ghaderi A
    Cancer Genet Cytogenet; 2007 Feb; 173(1):38-42. PubMed ID: 17284368
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.
    Rabban JT; Barnes M; Chen LM; Powell CB; Crawford B; Zaloudek CJ
    Am J Surg Pathol; 2009 Aug; 33(8):1125-36. PubMed ID: 19440148
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Effect of neoadjuvant chemotherapy on estrogen and progesterone receptors and P53 and CerbB-2 in breast cancer].
    Bao G; Yang DQ; Zhou B; Liu P; Wang S; Cheng L
    Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(40):2843-5. PubMed ID: 18167290
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stage of breast cancers found during the surveillance of women with a familial or hereditary risk.
    Kaas R; Muller SH; Hart AA; Rutgers EJ
    Eur J Surg Oncol; 2008 May; 34(5):501-7. PubMed ID: 17555911
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Polymorphisms in BRCA2 resulting in aberrant codon-usage and their analysis on familial breast cancer risk.
    Yang R; Chen B; Hemminki K; Wappenschmidt B; Engel C; Sutter C; Ditsch N; Weber BH; Niederacher D; Arnold N; Meindl A; Bartram CR; Schmutzler RK; Burwinkel B
    Breast Cancer Res Treat; 2009 Nov; 118(2):407-13. PubMed ID: 19229607
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
    Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
    Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transitional cell metaplasia of fallopian tube fimbriae: a potential mimic of early tubal carcinoma in risk reduction salpingo-oophorectomies from women With BRCA mutations.
    Rabban JT; Crawford B; Chen LM; Powell CB; Zaloudek CJ
    Am J Surg Pathol; 2009 Jan; 33(1):111-9. PubMed ID: 18830124
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients.
    Alsner J; Jensen V; Kyndi M; Offersen BV; Vu P; Børresen-Dale AL; Overgaard J
    Acta Oncol; 2008; 47(4):600-7. PubMed ID: 18465328
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Histopathological criteria and selection algorithms for BRCA1 genetic testing.
    Gadzicki D; Schubert A; Fischer C; Milde S; Lehmann U; Steinemann D; Lück HJ; Kreipe H; Schlegelberger B
    Cancer Genet Cytogenet; 2009 Mar; 189(2):105-11. PubMed ID: 19215791
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Loss of heterozygosity of p53, BRCA1, VHL, and estrogen receptor genes in breast carcinoma: correlation with related protein products and morphologic features.
    Otis CN; Krebs PA; Albuquerque A; Quezado MM; San Juan X; Sobel ME; Merino MJ
    Int J Surg Pathol; 2002 Oct; 10(4):237-45. PubMed ID: 12490973
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.